Teva Pharmaceuticals

Laser-focused on delivering on our strategy, we invite you to tune in to our live Q1 earnings call with CEO Richard Francis and the Teva leadership team, on Wednesday, May 7. Save the date here: https://ow.ly/WVow50VKuuo #QuarterlyResults #Q1Results #Earnings #Tevapharm

We are pleased to announce that RADICAVA® (edaravone) IV infusion will be listed on the Pharmaceutical Benefits Scheme (PBS) in Australia from 1st May 2025 [1]. RADICAVA is used to treat amyotrophic lateral sclerosis (ALS) and is indicated for adults who are independent in daily activities, have normal respiratory function, and begin treatment within two years of disease onset. At Teva, we deeply understand that ALS places a profound physical, emotional and financial strain on individuals and their families. This milestone underscores our unwavering commitment to scientific innovation and, most importantly, to the patients, families, and caregivers at the heart of our mission. This achievement also exemplifies Teva's ongoing dedication to improving lives through access to meaningful therapies. It reaffirms our commitment to advancing treatments that matter, easing burdens, and bringing hope to those facing this challenging diagnosis. Together, we believe in the power of science, compassion, and the unyielding human spirit. RADICAVA is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients (including sulfite). The most common side effects with RADICAVA are changes in the way you walk, bruising, headache, fungal infections, skin rashes or sugar in the urine. For more information about RADICAVA, including common side effects, precautions, warnings and interactions, please view the Consumer Medicine Information (CMI) [2]. #TevaAustralia #ALS #RADICAVA REFERENCES: [1] The Pharmaceutical Benefits Scheme (PBS) http://www.pbs.gov.au [2] Consumer Medicine Information (CMI) https://lnkd.in/gwzWuXAS

Teva recently launched a Train the Trainer program globally — enabling a group of passionate colleagues to become facilitators, mentors, and catalysts for improvement within their own functions. Teva India and GBS teams are driving excellence and innovation and contributing to our Pivot to Growth strategy. We are growing capabilities from within and empowering our people - one step at a time. Pooja Singh Vinod Shetty Raghunandan N #TevaIndia #LeanSixSigma #TrainTheTrainer #Transformation #GBS #GCC #OperationalExcellence #PivotToGrowth

I have a long-standing belief that curiosity powers innovation. It is the fundamental driving force of science and fuels our research and development work here at Teva. From our anti-TL1A program for Inflammatory Bowel Disease (IBD) and our dual-action rescue inhaler in development for children and adults living with asthma to our investigational once-monthly subcutaneous long-acting injection of olanzapine for schizophrenia, we are exploring new treatments in neuroscience, immunology and rare disease. Our curiosity to find what’s next in science – mixed with Teva’s culture of resilience and commitment to patients – keeps driving us forward to discover new and best-in-class molecules, treatments, therapies and platforms. The future of R&D is now. Watch us go! #TevaPharm #TheFutureOfRnDIsNow #TevaRnDThePlaceToBe #InnovativeMedicines #WeAreAllInForBetterHealth

Patient-centric innovations and improved device technologies are improving drug delivery solutions for the benefit of patients. Hear more about these key trends from Mark DeStefano, Director of Global Technology Innovation for the Combination Product and Device R&D group: https://ow.ly/tcb650VAb85 #Tevapharm

If you ask your favorite AI tool for suggestions on how to celebrate #EarthDay, it will surely have "spend time in nature" at the top of the list. But what if spending time in nature is a problem? Many of us have lingering fears of the dark, getting lost, or being caught off-guard. Being out in the wilderness (even if it's walking in the woods close to home) can amplify those fears and cause us stress. Read Claire Eastham's coping strategies for overcoming nature-related anxiety in 4 self-paced steps: https://ow.ly/Pj8l50VAaTO #EarthDay #Tevapharm

Biologics are complex medicines made by living cells that can, because of their larger and more complex molecular structure, provide precise and personalized treatments with potentially fewer side effects and safety concerns. Therapeutic antibodies are now being explored for their potential in treating infectious and neurodegenerative diseases, metabolic disorders, and cardiovascular conditions, showcasing their expanding role in modern medicine. Working across immunology and neuroscience, Teva is focused on identifying highly targeted antibodies to fight disease. With recent launches and an extensive pipeline, Teva has acquired industry-leading experience in screening and selecting disease-fighting antibodies for effective therapies. Discover more about Teva’s innovative work in this space: https://ow.ly/CVQM50VzNiW #Tevapharm

Want to hear more about the latest trends in clinical studies? From study accelerations and improved technology, including AI, to diversity action plans, Nageshwar Thudi Ph.D, Head of Teva’s Global Clinical Operations Innovative Medicine and Biosimilars organization, outlines the latest moves: https://ow.ly/J0yW50VzQIw #IndustryTrends #ClinicalStudies #Tevapharm

Research confirms: Making art isn’t just enjoyable - it’s actually therapeutic. Studies show that creating (and even viewing!) art can positively impact our brain - reducing stress, building empathy, and lifting mood*. This insight has inspired the work of one of our #HumanizingHealth Awards winners, Fundación Artepaliativo in Spain, which uses art therapy to support girls living with rare neurological and developmental disorders. They’ve created a welcoming space that encourages self-expression, play, and creativity, and builds emotional wellbeing. Since, for anyone living with a chronic illness, the emotional journey is often just as challenging as the physical one. Initiatives like this deeply connect with our purpose: We are all in for better health. Learn more about our Humanizing Health Awards, which support local organizations that bring comfort, support, and hope to patients, carers, and families: https://ow.ly/9Xvs50VzLIU #HumanizingHealth #Art #Tevapharm *Source: https://ow.ly/q67O50VzLIT

Can you imagine taking a medicine and realizing it doesn’t work for you? Or even worse, it has adverse effects because the studies weren’t based on people like you? For many people around the world, this is the reality. It highlights why incorporating diversity into clinical trials isn’t just a nice-to-have but a must-have. From designing inclusive clinical trials that benefit ALL people to understanding the impact of culture on patient care, Teva’s R&D global team leaders share their insights on the power of diversity in the development of new therapies: https://ow.ly/PBih50Vwl3t And what was Eric A. Hughes, MD, PhD’, Head of Global R&D, “Aha moment?” See below to find out. Eran Harary, MD Irit Hovich Anna Elgart Heather De Luca #DiversityAndInclusion #Tevapharm #Innovation #MedicineDevelopment